Normunity (@normunity) header
Normunity (@normunity) profile picture

Normunity

@normunity

Biotechnology company creating a new class of precision immuno-oncology medicines called immune normalizers that free the body’s normal immunity against cancer.

 Boston, MA and West Haven, CT
normunity.com/
Joined October 2022
  • Tweets12
  • Following4
  • Followers34
8Media
Photo by Normunity (@normunity)Photo by Normunity (@normunity)Photo by Normunity (@normunity)Photo by Normunity (@normunity)Photo by Normunity (@normunity)Photo by Normunity (@normunity)Photo by Normunity (@normunity)Photo by Normunity (@normunity)
With new #startup, immunotherapy pioneer Lieping Chen tries to turn ‘cold’ tumors ‘hot’ biopharmadive.com/news/normu… $NXTC $AZN $BMY $MRK
With new startup, immunotherapy pioneer Lieping Chen tries to turn ‘cold’ tumors ‘hot’

With new startup, immunotherapy pioneer Lieping Chen tries to turn ‘cold’ tumors ‘hot’

Chen, who discovered the cancer-protecting protein PD-L1, will work closely with startup Normunity to find targets that can help the immune system reach ‘cold’ tumors.

biopharmadive.com
1
3
1
4
Normunity, which combines the words normal and immunity, is launching out of stealth with a $65 million Series A. The 15-month-old West Haven and Boston-based biotech wants to address T cell exclusion, or when T cells can’t get into tumors. endpts.com/pd-l1-pioneer-lie…
PD-L1 pioneer Lieping Chen, Rachel Humphrey spin out new biotech to break down the door on cold...

PD-L1 pioneer Lieping Chen, Rachel Humphrey spin out new biotech to break down the door on cold...

In 2015, Lieping Chen — the I/O researcher whose early work established the PD-1/PD-L1 as a cancer target and the co-founder of Amplimmune, bought out by AstraZeneca in a $500 million ...

endpoints.news
4
4
Load more